ArticleThe Journal of infectious diseases2016
An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.Expert opinion on drug discovery · 2024Review
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.Signal transduction and targeted therapy · 2023Review
- Comparative evaluation of protective immunity againstFrontiers in cellular and infection microbiology · 2023Article
- Animal Models in Human Adenovirus Research.Biology · 2021Review
- Review
- Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.Viruses · 2021Review
- Article
- Laboratory response checklist for infectious disease outbreaks-preparedness and response considerations for emerging threats.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2020Article
- Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: An immuno-informatics approach.Microbial pathogenesis · 2019Article
- Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.Human vaccines & immunotherapeutics · 2019Review
- Ebola: Lessons on Vaccine Development.Annual review of microbiology · 2018Review
- An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.Emerging microbes & infections · 2018Article
- Post-exposure treatments for Ebola and Marburg virus infections.Nature reviews. Drug discovery · 2018Review
- From bench to almost bedside: the long road to a licensed Ebola virus vaccine.Expert opinion on biological therapy · 2018Review
- A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.Scientific reports · 2018Article
- The changing landscape of clinical trial and approval processes in China.Nature reviews. Clinical oncology · 2017Review
- Recombinant vaccines of a CD4+ T-cell epitope promote efficient control of Paracoccidioides brasiliensis burden by restraining primary organ infection.PLoS neglected tropical diseases · 2017Article
- Ebola and Marburg virus vaccines.Virus genes · 2017Review
- Evaluating the frequency of asymptomatic Ebola virus infection.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 6 institutions in 3 countries.
Funding
Abstract
A licensed vaccine against Ebola virus (EBOV) remains unavailable, despite >11 000 deaths from the 2014-2016 outbreak of EBOV disease in West Africa. Past studies have shown that recombinant vaccine viruses expressing EBOV glycoprotein (GP) are able to protect nonhuman primates (NHPs) from a lethal EBOV challenge. However, these vaccines express the viral GP-based EBOV variants found in Central Africa, which has 97.3% amino acid homology to the Makona variant found in West Africa. Our previous study showed that a recombinant adenovirus serotype 5 (Ad5)-vectored vaccine expressing the Makona EBOV GP (MakGP) was safe and immunogenic during clinical trials in China, but it is unknown whether the vaccine protects against EBOV infection. Here, we demonstrate that guinea pigs immunized with Ad5-MakGP developed robust humoral responses and were protected against exposure to guinea pig-adapted EBOV. Ad5-MakGP also elicited specific B- and T-cell immunity in NHPs and conferred 100% protection when animals were challenged 4 weeks after immunization. These results support further clinical development of this candidate and highlight the utility of Ad5-MakGP as a prophylactic measure in future outbreaks of EBOV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.